{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:29:13Z","timestamp":1788791353896,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12885-017-3176-x","type":"journal-article","created":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T08:45:04Z","timestamp":1489653904000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States"],"prefix":"10.1186","volume":"17","author":[{"given":"Chadi","family":"Nabhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Mato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Grinblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Lamanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Davids","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene S.","family":"Swern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shriya","family":"Bhushan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Dawn","family":"Flick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Kiselev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff P.","family":"Sharman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,16]]},"reference":[{"key":"3176_CR1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","volume":"65","author":"RL Siegel","year":"2015","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5\u201329.","journal-title":"CA Cancer J Clin"},{"key":"3176_CR2","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1182\/blood-2013-05-498287","volume":"122","author":"M Hallek","year":"2013","unstructured":"Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Blood. 2013;122:3723\u201334.","journal-title":"Blood"},{"key":"3176_CR3","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","volume":"370","author":"D Catovsky","year":"2007","unstructured":"Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007;370:230\u20139.","journal-title":"Lancet"},{"key":"3176_CR4","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2005-06-2395","volume":"107","author":"BF Eichhorst","year":"2006","unstructured":"Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006;107:885\u201391.","journal-title":"Blood"},{"key":"3176_CR5","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2006.08.0762","volume":"25","author":"IW Flinn","year":"2007","unstructured":"Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol. 2007;25:793\u20138.","journal-title":"J Clin Oncol"},{"key":"3176_CR6","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"376","author":"M Hallek","year":"2010","unstructured":"Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164\u201374.","journal-title":"Lancet"},{"key":"3176_CR7","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","volume":"370","author":"V Goede","year":"2014","unstructured":"Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370:1101\u201310.","journal-title":"N Engl J Med"},{"key":"3176_CR8","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","volume":"385","author":"P Hillmen","year":"2015","unstructured":"Hillmen P, Robak T, Janssens A, Babu KG, Kloczko J, Grosicki S, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet. 2015;385:1873\u201383.","journal-title":"Lancet"},{"key":"3176_CR9","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997\u20131007.","journal-title":"N Engl J Med"},{"key":"3176_CR10","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1200\/JCO.2013.49.6547","volume":"32","author":"P Hillmen","year":"2014","unstructured":"Hillmen P, Gribben JG, Follows GA, Milligan D, Sayala HA, Moreton P, et al. Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: final analysis of an open-label phase II study. J Clin Oncol. 2014;32:1236\u201341.","journal-title":"J Clin Oncol"},{"key":"3176_CR11","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.3109\/10428194.2014.898758","volume":"55","author":"C Nabhan","year":"2014","unstructured":"Nabhan C, Aschebrook-Kilfoy B, Chiu BC, Smith SM, Shanafelt TD, Evens AM, et al. The impact of race, ethnicity, age, and sex on clinical outcome in chronic lymphocytic leukemia: a comprehensive surveillance, epidemiology, and end results analysis in the modern era. Leuk Lymphoma. 2014;55:2778\u201384.","journal-title":"Leuk Lymphoma"},{"key":"3176_CR12","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1182\/blood-2007-12-129379","volume":"111","author":"H Brenner","year":"2008","unstructured":"Brenner H, Gondos A, Pulte D. Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. Blood. 2008;111:4916\u201321.","journal-title":"Blood"},{"key":"3176_CR13","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/bjh.14332","volume":"175","author":"AM Mato","year":"2016","unstructured":"Mato AM, Nabhan C, Kay NE, et al. Real-world clinical experience in the Connect\u00ae chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres. Br J Haematol. 2016;175:892\u2013903.","journal-title":"Br J Haematol"},{"key":"3176_CR14","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the national cancer institute-working group 1996 guidelines. Blood. 2008;111:5446\u201356.","journal-title":"Blood"},{"key":"3176_CR15","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/0021-9681(87)90107-X","volume":"40","author":"ME Charlson","year":"1978","unstructured":"Charlson ME, Sax FL, MacKenzie CR, Braham RL, Fields SD, Douglas Jr RG. Morbidity during hospitalization: can we predict it? J Chronic Dis. 1978;40:705\u201312.","journal-title":"J Chronic Dis"},{"key":"3176_CR16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"3176_CR17","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"E Kaplan","year":"1958","unstructured":"Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457\u201381.","journal-title":"J Am Stat Assoc"},{"key":"3176_CR18","first-page":"1137","volume-title":"A study of cross-validation and bootstrap for accuracy estimation and model selection","author":"R Kohavi","year":"1995","unstructured":"Kohavi R. A study of cross-validation and bootstrap for accuracy estimation and model selection, vol. 2. Montreal: Proceedings of the 14th International Joint Conference on Artificial Intelligence (IJCAI); 1995. p. 1137\u201345."},{"key":"3176_CR19","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/sim.1742","volume":"23","author":"LM Sullivan","year":"2004","unstructured":"Sullivan LM, Massaro JM, D\u2019Agostino Sr RB. Presentation of multivariate data for clinical use: the Framingham study risk score functions. Stat Med. 2004;23:1631\u201360.","journal-title":"Stat Med"},{"key":"3176_CR20","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.6004\/jnccn.2015.0137","volume":"13","author":"SG Mohile","year":"2015","unstructured":"Mohile SG, Velarde C, Hurria A, Magnuson A, Lowenstein L, Pandya C, et al. Geriatric assessment-guided care processes for older adults: a Delphi consensus of geriatric oncology experts. J Natl Compr Canc Netw. 2015;13:1120\u201330.","journal-title":"J Natl Compr Canc Netw"},{"key":"3176_CR21","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1002\/cncr.25292","volume":"116","author":"TD Shanafelt","year":"2010","unstructured":"Shanafelt TD, Rabe KG, Kay NE, Zent CS, Jelinek DF, Reinalda MS, et al. Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. Cancer. 2010;116:4777\u201387.","journal-title":"Cancer"},{"key":"3176_CR22","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00277-014-2048-6","volume":"93","author":"S Satram-Hoang","year":"2014","unstructured":"Satram-Hoang S, Reyes C, Hoang KQ, Momin F, Skettino S. Treatment practice in the elderly patient with chronic lymphocytic leukemia-analysis of the combined SEER and Medicare database. Ann Hematol. 2014;93:1335\u201344.","journal-title":"Ann Hematol"},{"key":"3176_CR23","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/cncr.28659","volume":"120","author":"LJ Nastoupil","year":"2014","unstructured":"Nastoupil LJ, Sinha R, Byrtek M, Zhou X, Taylor MD, Friedberg JW, et al. The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States. Cancer. 2014;120:1830\u20137.","journal-title":"Cancer"},{"key":"3176_CR24","doi-asserted-by":"crossref","first-page":"208","DOI":"10.4236\/jct.2014.52026","volume":"5","author":"BS DaCosta","year":"2014","unstructured":"DaCosta BS, Small A, Becker LK, Reyes CM. Differences in treatment patterns and health care costs among non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukemia patients receiving rituximab in the hospital outpatient setting versus the office\/clinic setting. J Cancer Ther. 2014;5:208\u201316.","journal-title":"J Cancer Ther"},{"key":"3176_CR25","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","volume":"127","author":"K Fischer","year":"2016","unstructured":"Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127:208\u201315.","journal-title":"Blood"},{"key":"3176_CR26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2014-02-556399","volume":"124","author":"N Pflug","year":"2014","unstructured":"Pflug N, Bahlo J, Shanafelt TD, Eichhorst BF, Bergmann MA, Elter T, et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 2014;124:49\u201362.","journal-title":"Blood"},{"key":"3176_CR27","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","volume":"17","author":"The International CLL-IPI working group","year":"2016","unstructured":"The International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17:779\u201390.","journal-title":"Lancet Oncol"},{"key":"3176_CR28","doi-asserted-by":"crossref","first-page":"5316","DOI":"10.1200\/JCO.2008.18.3996","volume":"26","author":"MN Levine","year":"2008","unstructured":"Levine MN, Julian JA. Registries that show efficacy: good, but not good enough. J Clin Oncol. 2008;26:5316\u20139.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-017-3176-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T16:45:05Z","timestamp":1568911505000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-017-3176-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,16]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["3176"],"URL":"https:\/\/doi.org\/10.1186\/s12885-017-3176-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,16]]},"article-number":"198"}}